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Abstract
Background: Scorpion stings cause an estimated 3000 deaths per annum worldwide. We conducted a systematic
review of all controlled clinical trials related to scorpion sting management.
Methods: We searched PubMed, EMBASE, Scopus, Web of Science and CINAHL and included controlled prospective
clinical trials (randomized or non-randomized). The following interventions were assessed: adults and children with
scorpion stings treated with (a) steroids vs. placebo, (b) different methods of pain relief, (c) antivenom vs. supportive
treatment, (d) prazosin vs. supportive treatment, (e) antivenom vs. prazosin and (f) antivenom plus prazosin vs. prazosin
alone. When trials had comparative outcomes, they were combined in a meta-analysis. Data was analysed with Review
Manager 5. Dichotomous data were compared with relative risk (RR), and continuous data were compared with mean
differences using a fixed effect model. There is no PROSPERO registration number for this study.
Results: Antivenom against Centruroides sp. are effective in reversing the clinical syndrome faster than no antivenom
treatment in children (RR, 0.02; 95% CI, 0.01 to 0.06; 322 participants; three trials). Antivenom (against Mesobuthus
tamulus) and prazosin combination is better than prazosin alone for faster resolution of symptoms (mean difference, −12.59 h;
95% CI, −14.01 to −11.17; 173 participants; three trials).
Conclusions: The polyvalent antivenom against Centruroides sp. in USA/Mexico and the monovalent antivenom againstM.
tamulus in India are effective for rapid resolution of symptoms. Prazosin is useful as an add-on therapy for M. tamulus stings.
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Background
Scorpion stings are a cause of significant morbidity and
mortality in Central and South America, Middle East,
Africa and South Asia [1]. Interestingly, despite the wide
geographical distribution of venomous scorpions, almost
all species that are harmful to humans belong to the
Buthidae family [1]. The scorpion has a stinger in their
terminal segment that has venom glands and uses it to
penetrate the skin of a potential target to inject venom.
The syndrome of scorpion envenoming is less heteroge-
neous than snake envenoming with all the major
manifestations being autonomic neuroexcitatory (stimu-
lation of both sympathetic and parasympathetic
systems). The main target of venom is voltage-gated
sodium channels [2]. Once the scorpion venom peptides
(scorpion α toxins) bind to these channels, their inacti-
vation is inhibited leading to prolonged depolarization
with neuroexcitation. Envenoming is characterized by
autonomic disturbances such as tachy/bradycardia,
hyper/hypotension, excessive salivation and lacrimation,
urinary and faecal incontinence and pulmonary oedema.
Deaths from scorpion stings are usually due to cardio-
genic shock and pulmonary oedema [3]. Stings are rarely
fatal in developed countries, but they are still a signifi-
cant cause of mortality in developing nations. It is esti-
mated that over one million scorpion stings (with
approximately 3000 deaths) occur every year in endemic
areas [4].
In this background it is essential to be clear about the
usefulness of current treatment strategies for scorpion
envenoming. The main modes of therapy for scorpion
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stings historically were supportive treatment and im-
munotherapy in form of antivenom. However, whether
antivenom added any advantage to standard supportive
therapy has been debated. The only meta-analysis pub-
lished on the topic in 2011 concluded that there was no
evidence for use of scorpion antivenom for old world
scorpion stings, but appropriate antivenom therapy en-
hanced recovery in new world scorpion stings [5]. These
observations were based on nine studies (four random-
ized controlled trials and five observational studies)
enrolling 687 patients. Four years have elapsed since the
publication of this meta-analysis, and immunotherapy is
a rapidly advancing field with novel evidence that has to
be taken in to account when recommending current
treatment strategies. Some reviewers have also expressed
concern over the generalizations made in this review as
the scorpion species are heterogeneous, and therefore,
the ‘presumed efficacy’ of antivenom cannot be general-
ized [6]. Also, it may not be prudent to combine studies
that tested different antivenoms (raised against venom of
different species in different geographical locations) for a
meta-analysis.
In addition to re-addressing the research question of
whether immunotherapy carries an advantage in scorpion
stings with more strict criteria, we also look into other
evidence-based treatment strategies that had been tested
in controlled clinical trials to date on scorpion stings.
Objectives
The objective of this study is to assess the usefulness
of treatment strategies and supportive measures for
symptom resolution in scorpion envenoming in




We included controlled clinical trials (randomized or
non-randomized) in this analysis. Case series where con-
trol populations were not available were excluded as they
did not provide data on comparative efficacy. However,
given the ethical constraints, we understand that it is diffi-
cult to enrol patients in to placebo arms for prospective
trials. Therefore, we also included studies that compared
prospectively enrolled patients with historical cohorts as
controls. Level of evidence for recommendations was
adjusted accordingly. Following a previously published
review by Abroug et al., we analysed the trials for old
world and new world scorpion stings separately [5].
Information sources and search strategy
We searched PubMed, EMBASE, Scopus, Web of
Science and CINAHL for relevant articles. PubMed was
searched with the keywords ‘scorpion’ in abstract and
‘trial’ in any field without any language, time or other
restrictions. EMBASE was searched with the keywords
scorpion and trial in the title or abstract with no
language or time limits. Scopus was searched with scor-
pion in title, keyword and abstract plus trial in title,
keyword and abstract without any language or time
limits. Web of Science and CINAHL were searched with
scorpion in abstract and trial in any field. We used the
software Endnote X3 (Thomson Reuters, Carlsbad, CA
92011, USA) to filter articles. The searches had a low
specificity to not to miss any relevant articles. The
search was repeated for all databases with keywords scor-
pion in title and abstract and ‘treatment’ or ‘treatment
strategy’ in any field to find any missed articles with the
previous strategy. Date of last search was 1st of December
2015. There is no PROSPERO registration number for this
study. The PRISMA checklist for this review is given as an
additional file (see Additional file 1: PRISMA checklist
2009.docx).
Study selection and data collection
We read all abstracts independently and identified key
articles by consensus. Depending on the abstracts, the
papers were classified as ‘yes’ (meets inclusion criteria),
‘no’ (does not meet inclusion criteria) and ‘doubtful’. Full
articles were obtained for all studies meeting the inclu-
sion (or doubtful) criteria, and there were no articles in
the doubtful category after reviewing the full articles. All
identified controlled trials on scorpion stings were cate-
gorized according to themes of their research questions.
Data items
The data items extracted from each eligible studies in-
cluded participant demographics, intervention and
control groups, drug doses, locality of study, species of
scorpions studied, severity scoring of symptoms,
duration for symptom resolution or improvement at 4 h
since initiation of treatment, adverse events attributable
to therapy and mortality rates.
Risk of bias
We assessed the risks of bias of included studies qualita-
tively using the Cochrane risk of bias assessment tool
[7]. We did not calculate quality scores for individual
studies as it is not perceived by all as an objective
measure of risk of bias [8].
Summary measures and synthesis of results
When comparative trials were available to combine in a
meta-analysis, we analysed the data using Review
Manager 5 [7]. Dichotomous data were compared with
relative risk (RR) and 95% confidence intervals (CI) and
continuous data with mean differences. A fixed effect
model was used for analysis. We assessed heterogeneity
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using the I2 statistic [9]. This examines the percentage of
total variation across studies that are due to heterogen-
eity rather than chance. When heterogeneity was
present, a random effect model was used for analysis.
The comparabilities and limitations of each study in-
cluded in the meta-analyses is given in Table 1.
Risk of bias across studies
We could not construct funnel plots to assess publica-
tion bias as there were only a few studies per each
comparison (less than three per comparison).
Results
Study selection
A total of 293 studies were identified from database
searches. After removal of duplicates and filtering
according to eligibility criteria, 11 studies remained.
Eight of these were included in the quantitative analyses
(meta-analyses). A flow diagram gives the details of
selection process (Fig. 1).
The characteristics of included studies (for meta-
analysis) are summarized in Table 2, and risk of bias of
each study is summarized in Fig. 2.
Effects of interventions
Steroids vs. placebo
There is only a single trial that had addressed this com-
parison. Abroug et al. assessed the effect of steroids
(intravenous hydrocortisone succinate 50 mg/kg, single
dose or six hourly up to a total dose of 12 g per day) vs.
placebo in Tunisia [3]. The commonly encountered
venomous scorpion species in this region were Androctonus
australis and Buthus occitanus. The trial was a well-
designed prospective randomized controlled trial with a
sample size of 600 patients (test arm—305, placebo
arm—295). All patients were enrolled only after a con-
firmed scorpion sting (either seen or captured), and other
medical treatment in both arms were similar except for
the steroids. Scorpion antivenom had been administered
for 25% of patients on the placebo arm and 20% of pa-
tients in the test arm. The severity of scorpion envenom-
ing was graded as 1 (local envenoming) or 2 (systemic
envenoming). Grade 2 envenoming was also comparable
between the groups (16.5 vs. 17%). There was no signifi-
cant difference in the overall hospital stay in either group
(steroid group, 0.52 ± 0.6; placebo group, 0.58 ± 0.8 days).
The occurrence of life-threatening complications of stings,
namely, shock (two in each group) and pulmonary
oedema (five in placebo group and seven in steroid group),
were also similar among the groups. There were only two
fatalities in the study, one in each study arm. Overall, it
was concluded that administration of steroids did not have
any added benefit. There are no other trials to re-confirm
these findings independently.
Pain relief
A single randomized controlled clinical trial had been
carried out in Turkey to evaluate this important aspect
of scorpion sting management [10]. They evaluated three
methods of pain relief: paracetamol (1 g intravenous
single dose), topical 5% lidocaine and ice application
over the sting site. Pain in participants was assessed with
a visual analogue scale (VAS) at 30th, 60th, 120th and
240th minutes. If pain was inadequately controlled after
30 min, intravenous pethidine was given irrespective of
the randomization as rescue pain relief. A total of 130
patients were randomized to each of the three test arms,
and none of them had systemic envenoming (six patients
with systemic envenoming were excluded prior to
randomization). There was no significant difference in
the baseline VAS score in the three groups prior to pain
relief. All three modalities reduced pain. However, top-
ical lidocaine had a significant and superior analgesic
effect compared to other two modalities at 30 min post
application/administration (p < 0.001). There was no sig-
nificant difference between the other two methods [10].
Prazosin vs. supportive therapy
Evidence from observations and uncontrolled trials in
the 1980s in India suggested a beneficial role of prazosin,
a post synaptic alpha adrenergic blocker in mediating
the ill effects of autonomic hyperactivity from scorpion
stings [11, 12]. More specifically, these observations
were on patients stung by the Indian red scorpion
(Mesobuthus tamulus). It was suggested that prazosin
would reduce the preload and afterload to counteract
the hypertension caused by a catecholamine surge after
a scorpion sting.
The only controlled trial that assessed the role of pra-
zosin vs. no specific treatment is reported by Gupta in a
paediatric cohort (mean age 4–5 years) in India [13]. It
is a small study with 16 patients in the prazosin group
and 20 in the control group. The test group received
30 μg/kg/dose on presentation and after 3 h. Further,
doses were repeated 6 hourly in those with persistent
evidence of systemic envenoming (e.g. pulmonary
oedema). The author does not classify the enrolled sub-
jects according to severity of envenoming, and the
control group (treated with supportive care) is a historical
cohort. Overall, the occurrence of complications (enceph-
alopathy, pulmonary oedema, hyper/hypotension, myocar-
ditis) did not show a significant difference between the
two groups. However, the mortality (7 vs. 1) and mean
duration of hospital stay (71.5 vs. 46.3 h) were significantly
less in the prazosin-treated group.
A different study comparing intravenous dobutamine
vs. prazosin (n = 21, in each treatment arm, all paediatric
patients) concluded that recovery was faster (especially
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for complications such as pulmonary oedema) with
prazosin [14].
Antivenom vs. supportive therapy/placebo
We carried out two meta-analyses for this comparison
with following inclusion criteria for study selection: (a)
controlled studies evaluating antivenom vs. no anti-
venom for scorpion stings conducted up to 2015; (b) at
least one arm of the study (the test arm) had to be pro-
spectively enrolled (due to ethical reasons, it may be
difficult to enrol a placebo arm prospectively); and (c)
studies which had compared antivenom vs. prazosin
Table 1 Compatibilities and limitations for including studies in the meta-analysis
Clinical comparison and trials Compatibilities Limitations
Antivenom vs. placebo (old world scorpions)
Abroug et al. [15] and Belghith
et al. [16]
Both trials are from the same geographical
region
Other treatment had been prescribed at
clinicians discretion
Both trials conducted in the same time
frame
Findings are only applicable to the
mentioned scorpion species and the
particular antivenom tested
The antivenom was produced against the
same scorpion species: A. australis and
B. occitanus
Both trials had been published over
15 years ago
Dosage of antivenom was similar and was
capable of neutralizing more than 10LD50
of venom/ml
Both trials were randomized prospective
clinical trials
Severity grading of scorpion stings was
similar
Antivenom vs. placebo (new world scorpions)
Two trials by Boyer et al. [19, 20]
and one trial by LoVecchio
et al. [18]
All three trials conducted in close
geographical range (Arizona, USA
and Mexico)
Severity grading on admission done by
LoVecchio et al. only. Both other studies
report venom concentration on admission
by assays and give a descriptive analysis of
symptoms
All three trials used antivenom against
Centruroides sp.
The neutralizing capacity of (LD50 equivalent
in mice) administered antivenom reported
in one trial only (Boyer et al. 2013)
Symptom resolution at 4 h is reported in
two trials and can be inferred by reported
data in the third trial (LoVeccio et al.)
The differences in study design of the
included studies are explained in Table 1
All trials were on children or young adults
(2 trials enrolled within an age range of
6 months to 18 years while the third
included children under 2 years)
Trial findings and recommendations are
limited to Centruroides sp. In Central
America and Southern States of USA
Antivenom and prazosin vs. prazosin alone
Bawaskar et al. [23], Natu et al.
[22] and Pandi et al. [24]
All trials have been conducted in India Heterogeneity in age groups (however,
antivenom dosage was not dependent
on age)
All trials included antivenom against
M. tamulus
Other differences in study design are
explained in Table 2
All trials report the mean time to resolution
of symptoms
Two trials used the same protocol for
antivenom administration and severity
grading while the third (Natu et al.) used a
different protocol
All trials have used the same monovalent
antivenom from the same company
Interpretations and recommendations
limited to M. tumulus in India
The maximum amount of venom injected
per sting by M. tamulus is 1.5 mg and each
ml of antivenom neutralized 1.2–1.5 mg of
venom. All trials used at least 30 ml of
venom per patient irrespective of the age
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were separately evaluated (see the ‘Antivenom vs. prazo-
sin’ section). Following a previous meta-analysis by
Abroug et al., old and new world scorpions were
assessed separately [5]. The differences between this
meta-analysis and ours are explained in the ‘Discussion’
section. The details of included studies are given in
Table 2. The risk of bias is shown in Fig. 2.
Old world scorpions
In a trial published in 1999 from Tunisia, 825 consecutive
patients were randomized into antivenom (n = 412) or pla-
cebo (n = 413) groups [15]. The test and control groups
did not differ on demographic and clinical parameters at
baseline. Clinical severity of sting was graded as I (absence
of systemic manifestations) or II (presence of systemic
manifestations). The medication they received prior to
administration of antivenom/placebo was also similar and
consisted mostly of steroids and antihistamines. Twenty
millilitres of bivalent antivenom against A. australis and
B. occitanus was administered for the test group over
15 min while the controls received a placebo. The investi-
gators evaluated the participants at 4 h to decide on
admission. The effect of treatment was evaluated as pre-
ventive (stalled the worsening from grade I to II) and cure
(reversed manifestations from grade II to I). There was no
difference in cure/prevention rates as well as admission
rates at the end of 4 h of observation. For the admitted
patients, subsequent duration of hospital stay was also
similar between the groups. Two patients (one from each
group) succumbed to envenoming.
Two other studies (not randomized prospective trials)
with historical control groups have also suggested the
futility of antivenom treatment in the late 1990s in
Tunisia and Israel [16, 17]. Of these, the study by Sofer
et al. (included in the meta-analysis by Abroug et al.)
was excluded from further analysis as both ‘control’ and
test groups were retrospective comparisons [17]. The
study by Belghith et al. was included despite the anti-
venom group being a retrospective analysis but had been
recruited as a part of a different clinical trial and hence
expected to have well-maintained records [3, 16]. The
control group for this study was prospectively recruited.
We conducted a meta-analysis of the studies by
Belghith et al. and Abroug et al. using resolution of
clinical syndrome after 4 h since administration of anti-
venom as an end point. There was no benefit of anti-
venom administration compared to supportive therapy.
In fact, the pooled effect was significantly in favour of
the control group (RR, 1.38; 95% CI, 1.09 to 1.74; 1095
participants; two trials) (Fig. 3).
Regarding adverse events, anaphylactic shock during
antivenom administration was observed in a total of seven
patients out of 547 patients (1.3%) (both trials combined).
However, there were no deaths due to anaphylactic shock
or other side effects attributable to antivenom.
New world scorpions
Three trials on new world scorpion stings met the inclu-
sion criteria for inclusion in a meta-analysis [18–20].
Their methodological characteristics are discussed in
Table 2, and risk of bias is shown in Fig. 2. A study
included by Abroug et al. in their meta-analysis was ex-
cluded by us as both groups were retrospectively evalu-
ated leading to a considerable degree of bias [21]. There
was one new trial (which met the inclusion criteria) that
had been published since the first meta-analysis [19].
The first of the included studies, conducted by Boyer
et al. in Arizona, USA, showed a benefit of antivenom
administration for Centruroides sp. stings [20]. This
study was on children and had a very small sample size
(n = 8 for antivenom group and n = 7 for placebo group).
The antivenom used was developed against a venom mix
of Centruroides sp. found in Mexico and was purported
to be effective against C. sculpturatus prevalent in
Fig. 1 Flow diagram for selection of studies for the systematic review
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Table 2 Characteristics of included studies for meta-analyses
Studies and parameters Comments
Comparison Antivenom vs. standard therapy (new world scorpions)
Boyer et al. 2009 [20]
Methods Randomized double blind study
Participants Children and adults aged between 6 months and 18 years admitted to a paediatric intensive care unit within 5 h since a
scorpion sting
Interventions The test group (n = 8) received scorpion antivenom against Centruroides sp. while the control group (n = 7) received a
placebo. Dose: three vials diluted in 50 ml of saline. Both groups received similar supportive care.
Outcomes Resolution of clinical syndrome within 4 h of antivenom administration, cumulative midazolam dose required for sedation
and serum venom levels up to 4 h post admission, adverse events
Study location Arizona, USA
Boyer et al. 2013 [19]
Methods Controlled study with trial arm recruited prospectively and compared with a retrospective control group
Participants Children and adults aged between 6 months and 18 years admitted to a paediatric intensive care unit within 5 h since a
scorpion sting
Interventions The prospectively recruited subjects (n = 78) received scorpion antivenom against Centruroides sp. while the control group
(n = 97) had been managed without antivenom. Three vials of antivenom were administered within 10 min diluted in 50 ml
of saline. Two additional vials were administered at the discretion of the physician if symptoms had not resolved at 1 or 2 h
since the initial dose.
Outcomes Resolution of clinical syndrome within 4 h of antivenom administration, serum venom levels up to 4 h post admission
(in prospective group only), adverse events
Study location Arizona, USA and Morelos, Mexico
LoVecchio et al. 2003 [18]
Methods Observational study without randomization
Participants Children aged less than 2 years with either a witnessed scorpion sting or signs and symptoms consistent with scorpion
envenoming
Interventions Severity was graded on a scale of I–IV with grades III and IV having systemic envenoming. A subset of patients with grade III
and IV envenoming had received anti-Centruroides antivenom (1 vial diluted in 50 ml of saline, n = 86). Another 46 children
did not receive antivenom despite having grade III and IV envenoming. Criteria for administration of antivenom are not clear.
Outcomes Meantime for resolution/improvement of systemic envenoming, adverse events, deaths
Study location Arizona, USA
Comparison Antivenom vs. standard therapy (old world scorpions)
Abroug et al. 1999 [15]
Methods Prospective randomized controlled trial
Participants Patients with scorpion stings older than 10 years. A total of 825 patients were randomly allocated to test (n = 412) and
control arms (n = 413)
Interventions The test group received 20 ml of bivalent (A. australis and B. occitanus) scorpion antivenom. Both groups received supportive
care with steroids, fluid replacement, antihistamines and life-supporting measures for systemic envenoming as required.
Outcomes Severity was graded as I (no systemic envenoming) and II (systemic envenoming). Prevention was defined as non-progression
from grade I to II, and cure was defined as reversal of symptoms from grade II. Outcomes were defined after 4 h since
administration of antivenom or admission.
Other monitored outcomes were death, complications of envenoming and adverse effects attributable to antivenom.
Study location Tunisia
Belghith et al. 1999 [16]
Methods Retrospective analysis of a sub-population of patients enrolled for a clinical trial. Control group selected prospectively
Participants Patients with scorpion stings older than 10 years. One hundred and thirty five patients who were administered bivalent
antivenom for scorpion during a previous trial had their records re-examined and matched with controls on a
pair-match basis.
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Arizona based on in vitro binding affinity studies. The
outcomes assessed were resolution of clinical symptoms
at 4 h after antivenom infusion (primary end point), and
total dose of midazolam required to reduce agitation
and plasma venom levels at 1 and 4 h (secondary end
points). The group treated with antivenom showed a
significant resolution of neurotoxicity at 4 h (p = 0.001)
and a significantly lesser requirement for midazolam
(measured as total cumulative dose administered at 4 h)
(p = 0.01). Venom was undetectable in serum of all
children treated with antivenom at 1 h while six children
in placebo arm still had detectable venom (p = 0.001).
The second trial was also conducted by some of the
authors in the previous trial, and they had expanded the
scope of the trial to include centres in Mexico. The trial
arm was recruited prospectively while the control arm
was evaluated retrospectively probably due to ethical
constraints. The study protocol for antivenom adminis-
tration and outcomes assessed were similar to the
previous study mentioned in the paragraph above.
Table 2 Characteristics of included studies for meta-analyses (Continued)
Interventions No prospective intervention. Controls did not receive antivenom.
Outcomes Severity was graded as I (no systemic envenoming) and II (systemic envenoming). Prevention was defined as non-progression
from grade I to II, and cure was defined as reversal of symptoms from grade II. Outcomes were defined after 4 h since
administration of antivenom or admission.
Other monitored outcomes were death, complications of envenoming and adverse effects attributable to antivenom.
Study location Tunisia
Comparison Antivenom plus prazosin vs. prazosin
Bawaskar et al. 2011 [23]
Methods Randomised open label clinical trial
Participants Patients older than 6 months, reporting to hospital within 6 h of the sting and of grade II clinical severity (systemic
autonomic symptoms without shock). A total of 70 patients were randomized, 35 each to test and control groups.
Interventions The test group received Haffkine Biopharma monovalent scorpion antivenom (against M. tamulus) 30 ml dissolved in 100 ml
of normal saline and infused over 30 min. Both groups received either 250 μg (under 18 years of age) or 500 μg of oral
prazosin at 3 hourly intervals until the extremities were cold (resolution of peripheral vasodilatation).
Outcomes Primary endpoint: resolution of grade II clinical syndrome at 10 h and prevention of progression to a higher grade (III, IV
characterized by autonomic symptoms plus shock, pulmonary oedema)
Secondary endpoints: time to total resolution of clinical syndrome, total dose of prazosin required within 10 h and
adverse events
Study location Maharashtra, India
Natu et al. 2010 [22]
Methods Prospective open label clinical trial
Participants Patients aged 12–70 with a confirmed scorpion sting. The authors developed a composite clinical score based (minimum
and maximum scores were 0 and 25, respectively) on pulse rate, blood pressure, presence of priapism, sweating, pain and
neurological symptoms. Scores between 5 and 21 were included in the study. The enrolled were randomized into three trial
arms: prazosin alone (n = 25), prazosin and antivenom (n = 28) and antivenom alone (n = 28).
Interventions Haffkine monovalent antivenom was administered dissolved in distilled water (1:1) over 5–7 min intravenously. The total
dose of antivenom was decided based on composite clinical score and patient’s age. The doses varied between 20 and
80 ml. Prazosin was administered orally at 3 hourly intervals at a dose of 500 μg (<20 kg body wt) or 1 mg (>20 kg body wt).
Outcomes Primary endpoint: time to resolution of clinical symptoms
Study location Maharashtra, India
Pandi et al. 2014 [24]
Methods Randomized controlled trial
Participants Children aged less than 13 years were randomized into test (n = 25) and control (n = 25) groups. Grading of severity of sting
was as according to Bawaskar et al.
Interventions The test group received monovalent Haffkine antivenom according to protocol described by Bawaskar et al. Both groups
received prazosin at a dose of 30 μg/kg/dose at 3 hourly intervals until resolution of the clinical syndrome.
Outcomes Primary endpoint: time to resolution of clinical syndrome
Secondary endpoints: total dose of prazosin required, adverse events, prevention of worsening of clinical syndrome and
duration of hospital stay
Study location Pondicherry, India
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Seventy-eight patients received antivenom prospectively,
and only two remained symptomatic at 4 h since
administration. Of the historical cohort used as the
control, a vast majority (93/97, 95.6%) still remained
symptomatic at 4 h without antivenom. LoVecchio et al.
carried out a prospective study without randomization
for usefulness of anti-Centruroides sp. antivenom for
stings in children less than 2 years [18]. In this study, 86
patients were administered antivenom while 46 were
not. The mean recovery times of the two groups were
31 min (95% CI, 10–82 min) and 22.2 h (95% CI, 12–46 h),
respectively [18].
There were no deaths reported in any of the three tri-
als for new world scorpion stings in USA/Mexico. All
subjects were children or young adults. LoVecchio et al.
report serum sickness (defined as an unexplained rash
within 1–21 days since administration of antivenom)
in 49 (57%) patients. Other two trials do not mention
any diagnoses of anaphylaxis or serum sickness. All
adverse events recorded during follow-up are de-
scribed as ‘mild’.
In our meta-analysis, for new world scorpions
(Centruroides sp., using symptom resolution at 4 h as an
end point), there was a clear benefit in favour of anti-
venom administration (RR, 0.02; 95% CI, 0.01 to 0.06;
322 participants; three trials) (Fig. 4).
Antivenom vs. prazosin
The first published comparative study in this regard was
by Bawaskar et al. in 2007, comparing antivenom (n = 25)
against prazosin (n = 28). This was not a randomized
study. The antivenom had been administered in peripheral
healthcare centres prior to arrival at study hospital (which
had no involvement with the study), and variable doses of
antivenom had been given to patients without a proper
trial protocol. The patients arriving directly at the study
centre were treated with prazosin (without antivenom).
There were four deaths in the antivenom-treated group
vs. no deaths in the prazosin-treated group. The mean re-
covery time was also longer in the antivenom-treated
group. Authors state that the mean time lapse from sting
to arrival at hospital and degree of envenoming (measured
by number of patients with autonomic disturbances at
presentation) were reasonably similar between the two
groups. However, overall, this comparison provides poor
quality evidence due to methodological faults.
In contrast, in the prospective controlled trial by Natu
et al. (described below and in Table 2), there were two
trial arms treated with prazosin alone and antivenom
Fig. 3 Forest plot for comparison of antivenom vs. placebo/supportive therapy for old world scorpion stings (outcome: symptom resolution at
4 h as an end point)
Fig. 2 Risk of bias table for included studies (for meta-analyses)
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alone (in addition to a third trial arm treated by a
combination of antivenom and prazosin) [22]. In com-
parison, the antivenom-treated group had a significantly
improved recovery time compared to the prazosin-
treated group (mean difference, −15.1 h; 95% CI, −17.2
to −13.1). Regarding quality of evidence as per study
design, this observation is much stronger than the previ-
ous observation. It is also keeping in line with the overall
trend shown on the next comparison.
Antivenom plus prazosin vs. prazosin
For this comparison, all the available evidence is for old
world scorpion stings and from India. The commonest
venomous scorpion species associated with these trials is
Indian red scorpion (M. tamulus).
There were three trials that had compared antivenom
and prazosin against prazosin alone. They had also
measured at least one comparable outcome (mean
duration to resolution of clinical symptoms). All three
were prospective controlled studies within the same geo-
graphical region treating the same type of scorpion sting
which reduced heterogeneity. The details of the studies
are given in Table 2. The common risk of bias figure
demonstrates the risk of bias of each study.
Two trials had enrolled both adults and children [22, 23]
while one trial was restricted to children [24]. All trials had
used the same antivenom against M. tamulus from the
same manufacturer, and the dosage and administration
protocol was identical in two trials [23, 24]. These two
trials (Bawaskar et al. and Pandi et al.) have also catego-
rized severity grading of the envenoming using a similar
scale [23, 24]. The other trial by Natu et al. have made their
own clinical composite score to assess the severity of
envenoming, but that is also based on the same autonomic
disturbances, and they have excluded individuals with local
envenoming only and severe envenoming. Therefore, the
included patients are approximately comparable across the
studies with regard to clinical severity. The antivenom
doses used by Natu et al. had a wider range than the fixed
dose used by other two trials.
A meta-analysis of all three trials (common outcome of
mean duration to resolution of the clinical syndrome)
confirmed the superiority of combined therapy vs.
prazosin alone (mean difference, −12.59 h; 95% CI, −14.01
to −11.17; 173 participants; three trials) (Fig. 5).Of the
other outcomes reported, Bawaskar observed a significant
reduction in the total number of prazosin doses required
when the drug was combined with antivenom (mean
difference, −2.0; 95% CI, −2.5 to −1.6) [23]. There was no
significant difference in prevention of worsening to a
higher grade of envenoming between the two groups
though the numbers were more in the prazosin only
group. Pandi et al. also observed significant improvements
for both these outcomes in the combination treatment
group [24]. Natu et al. do not report on these outcomes.
There were no deaths in any of the trials and no signifi-
cant adverse events to antivenom administration. Natu et
al. have observed precipitation of pulmonary oedema in




The futility of steroids in scorpion envenoming is probably
explained from the fact that toxins do not induce an exten-
sive immune reaction in the immediate aftermath (within
Fig. 4 Forest plot for comparison of antivenom vs. placebo/supportive therapy for new world scorpion stings (outcome: symptom resolution at
4 h as an end point)
Fig. 5 Forest plot for comparison of antivenom and prazosin vs. prazosin alone for M. tamulus stings (old world scorpions, outcome: mean
duration for symptom resolution)
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4 h when a majority manifest systemic envenoming). The
envenoming is a result of functional disturbance of voltage-
gated sodium ion channels that lead to autonomic hyper-
excitability. Adrenal insufficiency, another mechanism via
which steroids were purported to show benefit, has not
been confirmed in humans following scorpion stings [3].
Overall, given the similarity of study arms of the quoted
trial with respect to confounding factors as well as the large
sample size, the evidence from this study can be considered
as good quality evidence.
Pain relief
The study by Aksel et al. was a well-designed prospect-
ive randomized trial with an adequate sample size.
However, it has two inherent sources of bias due to non-
blinding (which is probably unavoidable) and exclusion
of patients with severe envenoming. Doctors and prob-
ably patients also knew that lidocaine is a potent local
anaesthetic agent and that might have biased the VAS
scoring in favour of lidocaine. Also, exclusion of severe
envenoming limits the interpretation of results to mild
envenoming only. The pain perception and hence
response to analgesia in severe envenoming can vary sig-
nificantly from mild envenoming. Finally, the use of VAS
to report pain is highly subjective as different people
perceive pain differently. However, randomization would
have helped (at least partially) to offset this bias.
Prazosin vs. supportive therapy
The quality of evidence of the study by Gupta et al. [13]
is not strong from a methodological point of view given
the small sample size and the lack of a randomized
control group that was simultaneously enrolled. How-
ever, from an ethical point of view, it would have been
difficult to design a study that would not offer any treat-
ment against prazosin (given the prior observations of
its purported benefit). The status quo remains to this
date for this comparison. However, as mentioned in the
sections below, there is indirect evidence for a beneficial
role of prazosin in M. tamulus stings especially when it
is used as add-on therapy to antivenom.
Antivenom vs. supportive therapy/placebo
Given the heterogeneity of study designs (historical ana-
lysis vs. prospective controlled trials) and the taxonom-
ical differences in scorpion species concerned, it is
difficult to combine studies in a meta-analysis. One
alternative is to follow the approach adopted by an
earlier meta-analysis published in 2011 by Abroug et al.
which makes a clear distinction about antivenom against
old world and new world scorpions [5]. In this meta-a-
nalysis (Abroug et al.), there was a significant improve-
ment of symptoms with antivenom against new world
Centruroides sp. (risk difference, 0.53; 95% CI, 0.16 to
0.91; p < 0.001), but there was no such effect against old
world scorpions (risk difference, −0.05; 95% CI, −0.28 to
0.18; p = 0.65). The studies included in old world scor-
pions had been conducted in Tunisia, Israel and India
[15–17, 22, 25]. However, there were some methodo-
logical concerns regarding the included studies which
could have affected the quality of evidence. For example,
it had included studies where both test and control arms
were historical comparisons based on records. It was
also noted that some studies included in the first meta-
analysis had in fact compared antivenom against prazo-
sin, a treatment that probably has merit on its own [22,
25]. Multiple sources of bias (selection, detection,
reporting bias) and non-uniform data for outcome
reporting reduced the quality of evidence from this
meta-analysis which we attempted to avoid in our ana-
lysis (e.g. trials that had prazosin as a treatment are eval-
uated separately). The inclusion criterion for our meta-
analysis was described above.
Despite the more refined meta-analysis, the results
observed by us and Abroug et al. for this comparison
were similar. Our meta-analysis also confirmed a signifi-
cant benefit of symptom resolution with antivenom
against Centruroides sp. stings (new world scorpions)
but not with antivenom used against old world scorpions
in Tunisia. While trials for new world scorpions were
recent, those for old world scorpions were conducted
more than 15 years ago and from a single country. There
is plenty of scope to improve on this by further trials
covering different geographical locations and different
scorpion species. This should be a priority in toxino-
logical research.
Antivenom vs. prazosin
There are two studies that had assessed this comparison
with conflicting observations. Findings by Bawaskar et
al. favour prazosin while Natu et al. favour antivenom.
However, due to the methodological shortcomings in the
study by Bawaskar et al., the observations of Natu et al.
are more acceptable.
Antivenom plus prazosin vs. prazosin
There were three trials for this comparison all concern-
ing M. tumulus stings in India. They had used the same
antivenom preparation and assessed similar outcome
measures that were comparable to combine in a meta-
analysis which showed a significant benefit for the anti-
venom and prazosin combination. All the trials were
prospective controlled trials, and two of them were
randomized trials [23, 24] (randomization process is not
mentioned in the trial by Natu et al.). Age and sex of
participants as well as their baseline autonomic dis-
turbances were reported in all the trials and were not
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found to be different between the groups. Therefore, this
evidence can be considered as of good quality for
this therapeutic comparison against M. tamulus
stings in India.
Limitations
The methodological quality of most trials on scorpion
sting management does not meet the gold standard of
double blind randomized controlled studies. However,
ethical obligations and challenges in designing a blinded
randomized trial have to be taken into account with
regard to scorpion stings. The interpretations and rec-
ommendations regarding scorpion sting management
are restricted to the specific scorpion species (and hence
their geographical location) studied. From the available
data, useful recommendations can only be drawn for
Centruroides species in USA and Mexico and M.
tamulus in India.
Conclusions
Following conclusions can be summarized from all the
evidence presented above on various aspects of manage-
ment of scorpion stings for both old and new world
scorpion stings. The ‘antivenom’ mentioned below is not
a uniform entity. The trials have been carried out in only
a few countries, and recommendations are hence valid
within the context of these locations, scorpion species
and age group of participants. Therefore, we have
indicated these parameters in addition to the level of
evidence [26] within brackets of each recommendation.
For old world scorpions,
a) Steroids have no benefit in management of scorpion
stings (level of evidence, 2b; location, Tunisia;
common species, A. australis, B. occitanus;
applicable age group, children and adults over
10 years).
b) Local anaesthesia by topical lidocaine patches may
be superior to intravenous paracetamol or local ice
application for pain relief in mild envenoming (level
of evidence, 1b; location, Turkey; common species,
Androctonus crassicauda, Leiurus quinquestriatus,
Mesobuthus gibbosus and Mesobuthus eupeus;
applicable age group, adults over 18 years).
c) Prazosin may be better than supportive therapy
alone for stings by M. tamulus (level of evidence, 3b;
location, India; applicable age group, in children).
d) Polyvalent antivenom against A. australis and B.
occitanus were ineffective when compared to
placebo (level of evidence, 2a; location, Tunisia;
applicable age group, children and adults over
10 years).
e) Antivenom against M. tamulus may be better than
prazosin alone (level of evidence, 2b; location, India;
applicable age group, over 12 years of age).
f ) Antivenom (against M. tumulus) and prazosin
combination is better than prazosin alone (level of
evidence, 1b; location, India; applicable age group,
both adults and children over 6 months of age).
For new world scorpions,
a) Antivenom against Centruroides sp. are effective in
reversing the clinical syndrome faster than no
antivenom (level of evidence, 2a; location, Mexico
and USA; applicable age group, children and young
adults aged less than 18 years).
Additional file
Additional file 1: The PRISMA checklist. The PRISMA checklist for this
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